abstract Biologics have been a key component of severe asthma treatment, and there are
currently biologics available that target IgE, IL-5, IL-4/IL-13, and TSLP. Randomized …

Severe asthma is associated with an increased risk for exacerbations, reduced lung
function, fixed airflow obstruction, and substantial morbidity and mortality. The concept of …

This document provides clinical recommendations for the management of severe asthma.
Comprehensive evidence syntheses, including meta-analyses, were performed to …

Background Benralizumab is an IL5-receptor monoclonal antibody licensed for the treatment
of severe eosinophilic asthma (SEA). It has demonstrated efficacy in clinical trials in …

Severe asthma is a high-burden disease. Real-world data on mepolizumab in patients with
severe eosinophilic asthma is needed to assess whether the data from randomised …

Introduction Efficacy of mepolizumab, an anti-interleukin-5 monoclonal antibody, was
demonstrated in randomised controlled trials; data on its real-world impact in routine clinical …

Introduction Clinical remission as a multicomponent treatment goal in severe asthma is
being explored in clinical practice. This post hoc analysis used data from the REDES study …

Background Dupilumab is a monoclonal anti‐IL‐4Rα antibody developed for the treatment
of severe asthma (SA). An early access programme for dupilumab was opened in France in …

Background Patients with severe asthma may require maintenance oral corticosteroids
(mOCS) for disease control as well as systemic corticosteroid (SCS) bursts for clinically …

Background The efficacy of mepolizumab is well documented in severe eosinophilic asthma
(SEA), although the stringent selection criteria adopted by SEA clinical trials limits the …